leadf
logo-loader
viewHemoGenyx Pharmaceuticals
(
LSE:HEMO
)

Hemogenyx Pharmaceuticals to revolutionise bone marrow transplants

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals Plc (LON:HEMO), tells Proactive the biotech start up is focused on bringing to market products that could change the way bone marrow transplants are carried out.

''We're trying to develop new types of antibodies that will get rid of the need for chemotherapy and radiation''.

''These antibodies will prepare the patient in a much safer and targeted way ... reducing side effects and increasing the success rate of the transplantation''.

The company came about through a merger deal with Silver Falcon, a London-based shell company.

Quick facts: HemoGenyx Pharmaceuticals

Follow
LSE:HEMO

Price: 1.96 GBX

Market Cap: £19.2 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors. It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations...

on 27/6/18

2 min read